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ABSTRACT 
Objective: The present study was aimed to describe a simple, sensitive, 
rapid, accurate, precise and economical first derivative spectrophotometric 
method for the simultaneous determination of Mesalazine (MESA) and 
Rifaximin (RIFA) in synthetic mixture.  
Methods: The derivative spectrophotometric method was based on the 
determination of both the drugs at their respective zero crossing point 
(ZCP). The first order derivative spectra were obtained in 0.01 N NaOH 
and the determinations were made at 329.20 nm (ZCP of RIFA) for 
MESA and 292.80 nm (ZCP of MESA) for RIFA. The linearity was 
obtained in the concentration range of succinate 10-50 μg/ml for MESA 
and 10-50 μg/ml for RIFA. 
Results: The limit of determination was 0.321 μg/ml and 0.301 μg/ml for 
MESA and RIFA, respectively. The limit of quantification was 0.974 
μg/ml and 0.912 μg/ml for MESA and RIFA, respectively. The mean 
recovery was 100.20 and 99.52% for MESA and RIFA, respectively. The 
method was found to be simple, sensitive, accurate and precise and was 
applicable for the simultaneous determination of MESA and RIFA in 
synthetic mixture. The results of analysis have been validated statistically 
and by recovery studies. 
Conclusions: The method was successfully applied to pharmaceutical 
synthetic mixture which is considered in approved patent which show no 
interference. The result of analysis has been validated statistically and by 
recovery studies. So, this method accurate, precise, robust, rugged and 
economic in nature. 
Keywords: Mesalazine, Rifaximin, First order derivative method,  Spectroscopic 
method 
 
Introduction 
Mesalazine (MESA) and Rifaximin (RIFA) use 
for Inflammatory Bowel Disease. MESA is used 
as in anti-inflammatory agent, steroidal. 
Rifaximin is used in Gastrointestinal Agents, 
Anti-infective agent. The use of Rifaximin in 
combination with MESA has been proved to 
provide beneficial effect in inflammatory bowel 
disease. The mechanism of MESA and RIFA is 
quite different. MESA and RIFA are two 
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different types of drugs offering some 
symptomatic relief to the IBD patients. MESA 
treats inflammation, whereas, RIFA reduces bio 
burden. MESA and RIFA novel combination 
used in treatment of inflammatory bowel disease 
Patented by Lupin Ltd, WIPO WO2009047801 
A1.1  
MESA 
 
Figure 1: Chemical structure of MESA. 
MESA is a salicylate, its therapeutic effect does 
not appear to be related to cyclooxygenase 
inhibition; indeed, traditional non-steroidal anti-
inflammatory drugs actually may exacerbate 
inflammatory bowel disease. Although the 
mechanism of action of MESA is not fully 
understood, it appears to be topical rather than 
systemic. Mucosal production of Arachidonic 
acid metabolites, both through the 
cyclooxygenase pathways, i.e., prostanoids, and 
through the lipoxygenase pathways, i.e., 
leukotrienes and hydroxyeicosatetraenoic acids, 
is increased in patients with chronic 
inflammatory bowel disease, and it is possible 
that MESA diminishes inflammation by 
blocking cyclooxygenase and inhibiting 
prostaglandin production in the colon. MESA 
appears to diminish inflammation by inhibiting 
cyclooxygenase and lipoxygenase, thereby 
decreasing the production of prostaglandins, and 
leukotrienes and hydroxyeicosatetraenoic acids 
(HETs) respectively.it is also believed acts as a 
scavenger of oxygen-derived free radicals, 
which are produced in greater in patients with 
IBD.2 
MESA is chemically 5-Amino-2-Hydroxy-
benzoic acid. It is a appears as off white to gray, 
having molecular weight 153.14 g/mol.3-5 
 
RIFA 
 
Figure 2: Chemical structure of RIFA. 
Rifaximin is a semisynthetic, rifamycin-based 
non-systemic antibiotic, meaning    that the drug 
will not pass the gastrointestinal wall into the 
circulation as is common for other types of 
orally administered antibiotics. It is used to treat 
diarrhea caused by E. coli. Rifaximin acts by 
inhibiting RNA synthesis in susceptible bacteria 
by binding to the beta-subunit of bacterial 
deoxyribonucleic acid (DNA)-dependent 
ribonucleic acid (RNA) polymerase enzyme. 
This results in the blockage of the translocation 
step that normally follows the formation of the 
first phosphodiester bond, which occurs in the 
transcription process.6     
Rifaximin is chemically (7S,9E,11S,12R,13S, 
14R,15R,16R,17S,18S,19E,21Z)-2,15,17,36-
tetrahydroxy-11-methoxy-3,7,12,14,16,18, 
22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27, 
33-triazahexacyclo[23.10.1.1⁴,⁷.0⁵,³⁵.0²⁶,³⁴.0²⁷, 
³²] heptatriaconta 1,3, 5(35),9, 
19,21,25(36),26(34),28,30,32-undecaen-13-yl 
acetate. It is a Red Orange Crystalline Powder 
having molecular weight 785.87 g/mol.7,8  
The review of literature regarding quantitative 
analysis of MESA and Rifaximin revealed that 
no Simultaneous Equation method attempt was 
made to develop analytical methods for MESA 
and RIFA. Some spectrometric methods and 
chromatographic methods have been reported 
for the estimation of the individual and 
combination of drugs. The focus of the present 
study was to develop and validate a rapid, stable, 
specific, and economic Spectroscopic method 
for the estimation of MESA and RIFA in 
synthetic mixture. 
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Theory9  
We can find out concentration of both the drug 
from combination mixture using the linearity 
equation. In this method using the absorbance of 
both the drug and mixture at their wavelength 
and put this value in following equation and we 
can find out the concentration of drugs present 
in combination. 
Y = mx + c -------------------------------------- (1) 
Where, 
Y = Absorbance 
m = Slop 
x = Concentration 
c = Intercept 
Materials and Methods 
Apparatus 
A double beam UV/Visible spectrophotometer 
(Shimadzu model 2450, Japan) with spectral 
width of 2 nm, 1 cm quartz cells was used to 
measure absorbance of all the solutions. Spectra 
were automatically obtained by UV-Probe 
system software.  
An analytical balance (Sartorius CD2250, 
Gottingen, Germany) was used for weighing the 
samples. 
Sonicator (D120/2H, TRANS-O-SONIC), Class 
‘B’ volumetric glassware were used 
(Borosilicate), all instruments and glass wares 
were calibrated. 
Reference samples 
MESA and RIFA reference standard were 
supplied by CTX Life Sci. Sachin, Surat and 
Lupin LTD, Ankleshwar as a gift sample 
respectively. 
Materials and reagents 
Methanol AR Grade (FINAR), Distilled Water, 
NaOH AR Grade (RANCHEM), Distilled water, 
HCl (ASTRON) was used for development 
purpose.   
 
Preparation of standard solutions 
Preparation of stock solution of MESA 
Accurately weighed quantity of MESA 10 mg 
was transferred to 100 ml volumetric flask, 
dissolved, and diluted up to mark with 0.01 N 
NaOH to give a stock solution having strength 
100 µg/ml. 
Preparation of stock solution of RIFA 
Accurately weighed quantity of RIFA 10 mg 
was transferred into 100 ml volumetric flask, 
dissolved and diluted up to mark with 0.01 N 
NaOH to give a stock solution having strength 
100 µg/ml. 
Preparation of standard mixture solution 
(MESA + RIFA) 
4.0 ml of standard stock solution of MESA (100 
μg/ml) and 1.0 ml of standard stock solution of 
RIFA (100 μg/ml) were pipetted out into two 10 
ml volumetric flasks and volume was adjusted to 
the mark with 0.01 N NaOH to get 40 μg/ml of 
MESA and 10 μg/ml of RIFA. 
Preparation of test solution 
The preparation of synthetic mixture was as per 
patent. 
Mesalazine – 800 mg 
Rifaximin – 200 mg 
Na.CMC – 544 mg 
MCC - 416 mg 
Mg. stearate - q. s.   
Total= 2000 mg 
From that powder equivalent  to 100 mg of 
synthetic mixture in 100 ml  volume flask 
dissolve in 25 ml 0.01 N NaOH. Sonicate for 15 
min diluent up to the 100ml with 0.01 N NaOH 
and Shake Vigorously filter the solution. The 
solution was filtered and further diluted. 0.1 ml 
was withdrawn and made up to 10 ml that give 
40 ppm and 10 ppm of MESA and RIFA 
respectively. 
Methodology 
The standard solutions of NIF (10 μg/ml) and 
MET (50 μg/ml) were scanned separately in the 
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UV range of 200-400 nm. The zero-order 
spectra thus obtained was then processed to 
obtain first-derivative spectra. Data were 
recorded at an interval of 1 nm. The two spectra 
were overlain and it appeared that MESA 
showed zero crossing at 329.20 nm, while RIFA 
showed zero crossing at 292.80 nm. At the zero 
crossing point (ZCP) of RIFA (292.80 nm), 
MESA showed a first derivative absorbance, 
whereas at the ZCP of MESA (329.20 nm), 
RIFA showed a first-derivative absorbance. 
Hence 329.20 and 292.80 nm was selected as 
analytical wavelengths for determination of 
MESA and RIFA, respectively. These two 
wavelengths can be employed for the 
determination of MESA and RIFA without any 
interference from the other drug in their 
synthetic mixture formulation. 
First derivative conditions 
Mode : Spectrum 
Scan speed : Fast 
Wavelength range : 200-400 nm 
Derivative order : first 
Scaling factor: 50 
Results and Discussion 
Selection of wavelength and method 
development for determination of MESA and 
RIFA   
The standard solution of MESA and RIFA were 
scanned separately between 200-400 nm and 
zero-order spectra were not showed overlapping 
peaks. 
 
Figure 3: Overlain zero order spectra of 
MESA and RIFA, respectively. 
Thus obtained spectra were then processed to 
obtain first-derivative spectra. 
First order derivative spectrum for MESA 
showed zero crossing point: 329.20 nm. The 
wavelength selected for estimation of MESA 
was 292.80 nm because it showed r2>0.999 at 
this wavelength in mixture.  
First order derivative spectrum for RIFA showed 
zero crossing point: 292.80 nm. The wavelength 
selected for estimation of RIFA was 329.20 nm 
because it showed r2>0.999 at this wavelength in 
mixture (Figure 4). 
 
Figure 4: Overlain first order spectra of 
MESA and RIFA. 
 
Figure 5: Overlain first order spectra of 
MESA and RIFA in 4:1 ratios, respectively 
with the combination solution (4:1). 
Validation of proposed method 10 
Parameters to be considered for the validation of 
methods are: 
Linearity and range   
The first-derivative spectra (Figure 4) showed 
linear absorbance at 329.20 nm (ZCP of RIFA) 
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for MESA (10-50 μg/ml) and 292.80 nm (ZCP 
of MESA) for RIFA (10-50 μg/ml) with 
correlation coefficient (r2) of 0.9992 and 0.9993 
for MESA and RIFA, respectively. This method 
obeyed beer’s law in the concentration range 10-
50 μg/ml and 10-50 μg/ml for MESA and RIFA, 
respectively (Table 1). Correlation coefficient 
(r2) form calibration curve of MESA and RIFA 
was found to be 0.9992 (Figure 5.1.2) and 
0.9993 (Figure 5.1.3), respectively.  
 
Figure 5.1.1: Overlain linear first order 
spectra of MESA (Blue) and RIFA (Pink) in 
1:1 ratio. 
The regression line equation for MESA and 
RIFA are as following,  
   y = 0.0119x - 0.0576 for MESA ________ (1)  
   y = -0.0148x +0.0179 for RIFA______ (2) 
From the combination solution of MESA and 
RIFA the dilution were made in ratio of 1:1 and 
absorbance were recorded (Table1) and 
correlation coefficient (r2) of 0.9992 and 0.9993 
(Figure 5) for MESA and RIFA, respectively. 
Calibration curves for MESA 
This series consisted of five concentrations of 
standard MESA solution ranging from 10-50 
μg/ml. The solutions were prepared by pipetting 
out Standard MESA stock solution (1.0 ml, 2.0 
ml, 3.0 ml, 4.0 ml, 5.0 ml) was transferred into a 
series of 10 ml volumetric flask and volume was 
adjusted up to mark with 0.01 N NaOH. A zero 
order derivative spectrum of the resulting 
solution was recorded and processed to first 
derivative spectra, measured the absorbance at 
329.20 nm against a reagent blank solution (0.01 
N NaOH). Calibration curve was prepared by 
plotting absorbance versus respective 
concentration of MESA. 
Calibration curve for RIFA 
This series consisted of five concentrations of 
standard RIFA solution ranging from 10-50 
μg/ml. The solutions were prepared by pipetting 
out Standard RIFA stock solution (1.0 ml, 2.0 
ml, 3.0 ml, 4.0 ml, 5.0 ml) was transferred into a 
series of 10 ml volumetric flask and volume was 
adjusted up to mark with 0.01 N NaOH.  A zero 
order derivative spectrum of the resulting 
solution was recorded and processed to first 
derivative spectra, measured the absorbance at 
292.80 nm against a reagent blank solution (0.01 
N NaOH). Calibration curve was prepared by 
plotting absorbance versus respective 
concentration of RIFA. 
Precision  
Intraday precision  
Table 1: Calibration data for MESA and RIFA at 329.20 nm and 292.80 nm, respectively (n=6). 
MESA(ZCP for RIFA 292.80nm) RIFA(At ZCP for MESA329.20 nm) 
Conc. 
(µg/ml) 
Absorbance ± SD 
(n=6) 
%RSD Conc. 
(µg/ml) 
Absorbance± 
SD(n=6) 
%RSD 
10 0.065±0.0005 0.849 10 0.125±0.0001 0.824 
20 0.172±0.0016 0.972 20 0.289±0.0012 0.419 
30 0.303 ±0.0021 0.723 30 0.423±0.0039 0.931 
40 0.414±0.0014 0.355 40 0.574±0.0027 0.475 
50 0.537±0.0012 0.225 50 0.724±0.0025 0.345 
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The data for intraday precision for combined 
standard solution of MESA and RIFA is 
presented in Table 2. The % R.S.D was found to 
be 0.157-0.506% for MESA and 0.211-0.464% 
for RIFA. These % RSD value was found to be 
less than ± 1.0 indicated that the method is 
precise. 
 
Figure 5.1.2: Calibration curve for MESA at 
329.20 nm. 
 
Figure 5.1.3: Calibration curve for RIFA at 
292.80 nm. 
Table 2: Intraday precision data for 
estimation of MESA and RIFA (n=3). 
 
Interday precision  
The data for interday precision for combined 
standard solution of MESA and RIFA is 
presented in Table 3. The% R.S.D was found to 
be 0.024-0.330% for MESA and0.211-0.468 
%for RIFA. These % RSD value was found to 
be less than ± 1.0 indicated that the method is 
precise. 
Table 3: Interday precision data for 
estimation of MESA and RIFA (n=3). 
Conc. 
(μg/ml) 
 
ZCP of RIFA 
292.80 nm 
ZCP of MES 
329.20 nm 
MESA 
+ 
RIFA 
Mean %RSD Mean %RSD 
10:10 0.062 0.024 0.123 0.468 
30:30 0.303 0.330 0.425  0.359 
50:50 0.535 0.285 0.721 0.211 
Accuracy 
From the synthesis mixture weighed accurately 
equivalent about 100 mg of RIFA. Four 100 ml 
Volumetric Flask was taken and in each flask 
added synthetic mixture equivalent to 10 mg of 
RIFA. Flask 1 formed as a Placebo and 
remaining flask 2, 3, 4 spike with 80, 100, 
120%.of Solid API. The same procedure for 
MESA was repeated. Content in 100 ml 
volumetric flask dissolved in 25 ml 0.01 N 
NaOH and Sonicate for 15 minutes was taken 
and made up the volume with 0.01 N NaOH up 
to 100 ml. The solution was filtered through 
Whatman filter paper No. 42. With the 
Mesalazine & Rifaximin with the ratio 
4:1dissolved in 0.01 N NaOH with small volume 
of Solvent, Sonicate for 15 mins, then made up 
to 100 ml with 0.01 N NaOH with all excipients. 
Now, this solution was used for further dilution. 
Total amount of formulation was taken in 100 
ml of volumetric flask and add 25 ml 0.01 N 
NaOH. 0.01 N NaOH was sonicated, filtered and 
made up to mark. From it 0.5 ml was diluted to 
10 ml with 0.01 N NaOH of 0%, 80%, 100% 
and 120% solution this accuracy method done 
by spiking method. Data from nine 
y = 0.0119x - 0.0576
R² = 0.9992
0
0.1
0.2
0.3
0.4
0.5
0.6
0 20 40 60
CONC.(µg/ml)
A
B
S
y = -0.0148x + 0.0179
R² = 0.9993
-0.8
-0.6
-0.4
-0.2
0
0 20 40 60
CONC.(µg/ml)
A
B
S
Conc. 
(μg/ml) 
 
 
ZCP of RIFA 
292.80 nm 
ZCP of 
MES 329.20 
nm 
 
MESA + 
RIFA 
 
Mean %RS
D 
Mean %RS
D 
  10:10 0.065 0.157 0.124 0.464 
      30:30 0.301 0.506 0.426  0.234 
   50:50 0.534 0.285 0.722 0.211 
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determinations over three concentration levels 
covering the specified range was determined and 
% recovery was calculated. The % recovery 
values are tabulated in Table 5. The value of 
%RSD within the limit indicated that the method 
is accurate and percentage recovery shows that 
there is no interference from the excipients. 
Limit of detection and quantitation  
The LOD for MESA and RIFA was conformed 
to be 0.321 μg/ml and 0.301 μg/ml respectively. 
The LOQ for MESA and RIFA was conformed 
to be 0.974 μg/ml and 0.912 μg/ml, respectively. 
The obtained LOD and LOQ results are 
presented in Table 6. 
Robustness and ruggedness  
The obtained Ruggedness and Robustness 
results are presented in Table 7. The %RSD 
value was found to be less than ± 1.0 indicated 
that the method is precise. No significant 
changes in the spectrums were observed, 
proving that the developed method is rugged and 
robust. 
Table 4: Amount of API. 
Amt. of API in 
synthetic mixture (mg) 
Amt. of API Spiking (mg) Total Amt. (mg) 
MESA           RIFA 
MESA RIFA      MESA RIFA   
    40 10 - - 40 10 
    40 10 32 8 72 18 
    40 10 40 10             80 20 
    40 10 48 12  88 22 
Table 5: Recovery data of MESA and RIFA (n=3). 
Level 
of 
recovery 
Total Conc. 
(µg/ml) 
Result of recovery study 
Total Quantity 
Found (µg/ml) 
% Recovery & %RSD 
MESA RIFA MESA RIFA MESA RIFA 
0% 20 5 20.12 4.95 100.4 0.175 99.13 0.709 
80 % 36 9 35.96 8.94 99.76 0.201 
 
98.83 0.958 
 
100 % 40 10 40.05 10.01 100.3 0.419 
 
100.0 0.529 
 
120 % 44 11 44.01 11.01 100.0 0.358 
 
100.1 0.255 
Mean of 3 Determinations 100.2 0.364 
 
99.52 0.6354 
Table 6: LOD and LOQ data of MESA and RIFA (n=10). 
Conc. (μg/ml) Avg. abs* ± SD 
(292.80nm) MESA 
% 
RSD 
Avg. abs*±SD 
(329.20nm) RIFA 
% RSD 
MESA RIFA 
20 20 0.175 ± 0.001 0.659 0.292 ± 0.001 0.461 
LOD (μg/ml) 0.321 0.301 
LOQ (μg/ml) 0.974 0.912 
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Application of the proposed method for 
analysis of MESA and RIFA synthetic mixture 
As per the title of my topic the development and 
validation was done by synthetic mixture. So for 
that stable formula from the patent was selected 
and as per the ratio the synthetic mixture was 
prepared. 
From that powder equivalent  to 100 mg of 
synthetic mixture in 100 ml  volume flask 
dissolve in 25 ml 0.01 N NaOH. Sonicate for 15 
min diluent up to the 100ml with 0.01 N NaOH 
and Shake Vigoursly filter the solution. & Filter 
the solution & further dilute. Withdraw 0.1 ml 
and make up to 10 ml that give 40 ppm and 10 
ppm of MESA and RIFA respectively. From the 
spectra of assay’s Zero order linearity of 
synthetic mixture converted to 1st Derivative 
spectra (4DL 50SF) of concentration 40 μg/ml 
and 10 μg/ml for MESA and RIFA respectively. 
A first order derivative spectrum of the sample 
solution containing 40 μg/ml of MESA and 10 
μg/ml of RIFA was recorded and the absorbance 
at 329.20 nm and 292.80 nm were noted for 
estimation of MESA and RIFA, respectively. 
The concentration of MESA and RIFA in 
mixture was determined using the corresponding 
calibration graph. The % assay values are 
tabulated in Table 8. 
Conclusions    
All the parameters are validated as per ICH 
guidelines for the method validation and found 
to be suitable for routine quantitative analysis in 
pharmaceutical dosage forms. The result of 
Table 7: Robustness and Ruggedness data of MESA and RIFA (n=3). 
Parameters  MESA 
(ZCP of RIFA 
292.80nm) 
RIFA 
(ZCP of MESA 
329.20nm) 
Mean %RSD Mean %RSD 
ROBUSTNESS 
Different  
instrument 
Inst. 1 0.174 0.876 0.292 0.342 
Inst. 2 0.176 0.568 0.290 0.526 
Different  
Analyst 
Analyst 1 0.175 0.871 0.291 0.523 
Analyst 2 0.176 0.866 0.290 0.344 
RUGGEDNESS 
Change  
wavelength 
292.60&293.00nm 0.189 0.806 0.307 0.497 
329.00&329.40nm 0.195 0.780 0.277 0.550 
Change  
Ratio 
1:1 0.175 0.871 0.292 0.342 
4:1 0.416 0.366 0.290 0.525 
1:4 0.175 0.571 0.578 0.173 
Solvent  
change 
0.0098N NaOH 0.176 0.465 0.168 0.465 
0.02  N NaOH 0.186 0.809 0.184 0.655 
Table 8: Analysis data of commercial formulation*(n=3). 
Sr.  
No. 
Formulation 
(synthetic 
mixture) 
 
Absorbance* 
(292.80nm) 
MESA 
% Assay 
MESA 
±SD 
Absorbance* 
(329.20nm) 
RIFA 
% Assay 
RIFA ±SD 
MESA RIFA 
1  
40 
 
10 
0.418 99.63 
 ± 0.30 
0.166 100.70 
 ± 0.70 2 0.417 0.165 
3 0.416 0.167 
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linearity, accuracy, precision proved to be within 
limits with lower limits of detection and 
quantification. Ruggedness and Robustness of 
method was confirmed as no significant were 
observed on analysis by subjecting the method 
to slight change in the method condition. Assay 
results obtained by proposed method are in fair 
agreement.  
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Change  Solvent 
Change in Wavelength 
0.465-0.809 
0.780-0.806 
0.465-0.655 
0.497-0.550 
11 Assay 100.50% 99.33% 
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